- Home
- LPRO vs QURE Comparison
LPRO vs QURE Comparison
Compare LPRO & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- QURE
- Stock Information
- Founded
- LPRO 2000
- QURE 1998
- Country
- LPRO United States
- QURE Netherlands
- Employees
- LPRO N/A
- QURE N/A
- Industry
- LPRO Finance: Consumer Services
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- QURE Health Care
- Exchange
- LPRO Nasdaq
- QURE Nasdaq
- Market Cap
- LPRO 712.5M
- QURE 691.2M
- IPO Year
- LPRO N/A
- QURE 2007
- Fundamental
- Price
- LPRO $5.17
- QURE $12.84
- Analyst Decision
- LPRO Buy
- QURE Strong Buy
- Analyst Count
- LPRO 8
- QURE 8
- Target Price
- LPRO $6.83
- QURE $39.43
- AVG Volume (30 Days)
- LPRO 457.9K
- QURE 820.4K
- Earning Date
- LPRO 03-04-2025
- QURE 03-03-2025
- Dividend Yield
- LPRO N/A
- QURE N/A
- EPS Growth
- LPRO N/A
- QURE N/A
- EPS
- LPRO 0.04
- QURE N/A
- Revenue
- LPRO $95,887,000.00
- QURE $28,587,000.00
- Revenue This Year
- LPRO N/A
- QURE $153.92
- Revenue Next Year
- LPRO $14.36
- QURE N/A
- P/E Ratio
- LPRO $135.33
- QURE N/A
- Revenue Growth
- LPRO N/A
- QURE N/A
- 52 Week Low
- LPRO $4.57
- QURE $3.73
- 52 Week High
- LPRO $8.14
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- LPRO 35.83
- QURE 38.20
- Support Level
- LPRO $5.34
- QURE $12.72
- Resistance Level
- LPRO $5.71
- QURE $14.42
- Average True Range (ATR)
- LPRO 0.29
- QURE 0.85
- MACD
- LPRO -0.11
- QURE -0.26
- Stochastic Oscillator
- LPRO 6.01
- QURE 7.26
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against losses from defaults.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.